CompletedNot Applicable

Rivaroxaban in Patients With Atrial Fibrillation Undergoing PCI

Germany1,632 participantsStarted 2018-01-01

Plain-language summary

This study evaluates the antithrombotic therapy in patients suffering from atrial fibrillation after stent implantation in Germany. Patients prescribed with the novel oral anticoagulant Rivaroxaban will be followed up over 14 months for their adherence to the medication schedule and for complications that occurred after index PCI.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years and capable of giving written informed consent * Known or newly diagnosed non-valvular atrial fibrillation * PCI with stent implantation during index hospital stay * Written informed consent for participation in observational study (incl. telephone follow-up) * Not simultaneously participating in any randomized trial Exclusion Criteria: * None

What they're measuring

Antithrombotic combination therapies (treatment patterns) in patients with non-valvular AF undergoing PCI

Timeframe: 18 months

Trial details

NCT IDNCT03315650

SponsorIHF GmbH - Institut für Herzinfarktforschung

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-03-31

View on ClinicalTrials.gov More Non-valvular Atrial Fibrillation trials